Abstract: Background. Recurrent head and neck squamous cell carcinoma (HNSCC) remains a difficult cancer to treat. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R]).
Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) remains 1 of the most difficult cancers to treat with limited chemotherapeutic options. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R]). In a tumor tissue biopsy of this patient, we observed a decreased level of dihydrofolate reductase (DHFR) and conversion of gene expression profile from cetuximab resistance to cetuximab sensitivity after AMG-479 treatment, suggesting that AMG-479 may have sensitized the tumor to MTX and cetuximab. This represents a promising approach to the implementation of IGF-1R inhibitors in refractory HNSCC.
CASE REPORT
A 54-year-old woman was referred to our hospital for the management of recurrent HNSCC in 2004. She was a nonsmoker and was initially diagnosed with T1N1M0 SCC of the oral tongue in September 2001. She underwent a right partial glossectomy with right suprahyoid neck dissection without adjuvant chemotherapy or radiation therapy. She remained clinically disease free until May 2003, when she developed a new mass in the right lower alveolar ridge and was treated with radiation therapy. She developed local recurrences on 3 subsequent occasions. She underwent surgical resections for the first 2 recurrences in December 2003 and May 2004, but when the mass recurred for the third time in March 2005, it was deemed inoperable and she was referred for palliative systemic chemotherapy. She was treated with a combination of cisplatin and irinotecan on a clinical trial until her disease progressed after 10 weeks of therapy. She then received weekly docetaxel; however, the disease progressed after 3 weeks and treatment was discontinued. Due to poor performance status, in July 2005 she was not considered a candidate for further cytotoxic chemotherapy and was started on cetuximab monotherapy. After 11 weeks of cetuximab, she experienced a complete clinical response, but her disease progressed after 18 months ( Figures 1A and 1D) . Cetuximab was discontinued in November 2006. In January 2007, she was enrolled in a phase I clinical trial and received 3 doses of AMG-479 12 mg/kg every 2 weeks. AMG-479 was discontinued due to the rapid progression of disease ( Figures 1B and 1E ). As the last effort for palliation, she was started on a low dose of weekly MTX 40 mg/m 2 in April 2007. After 12 weeks of MTX, she achieved a near-complete response and remained without progression for 6 months ( Figures 1C  and 1F ). In October 2007, she developed progressive disease while on MTX. At that point, the decision was made to re-challenge the tumor with cetuximab. The patient again experienced a significant clinical response as determined by consecutive measurements of the tumor size (decreasing from 10 Â 6 cm to 3 Â 3 cm within 3 weeks) and by palliation of her pain. However, this second response was brief. Unfortunately, her disease progressed in 8 weeks and she died in January 2008 under hospice care.
The clinical information was collected by a retrospective medical record review. Formalin-fixed paraffin-embedded tumor and adjacent normal mucosal epithelia from surgical resections in 2001 (original diagnosis) and 2004 (tumor recurrence after radiation therapy and before chemotherapies), and frozen tumors from biopsies post-cetuximab (pre-AMG-479) and post-AMG-479 treatments in 2007 were obtained under an Institutional Review Board-approved protocol. A signed consent form for publication of this case report was also obtained from the patient during her treatments. Biopsies from the tumor in 4 different time points and of normal mucosa from 2 different time points were available for translational studies.
Gene expression data were generated and analyzed in duplicate for each tumor, as previously described.
1 The AMG-479 modulated genes were determined by comparing the pre-AMG-479 and post-AMG-479 treatment frozen tumor biopsies. The biological relatedness of the selected genes was examined using Ingenuity Pathways Analysis (IPA). The protein levels of total and phosphorylated IGF-1R, protein kinase B (AKT), DHFR, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were determined by Western blots (IGF-1R, IGF-1R-Tyr1135/ 1136, AKT, and AKT-Ser473, Cell Signaling Technology, Danvers, MA; DHFR, BD Biosciences, San Jose, CA; and GAPDH, Santa Cruz Biotechnology, Santa Cruz, CA). Detection of human papillomavirus, and DNA mutation analyses of exons 18, 19, and 21 of epidermal growth factor receptor (EGFR), and codon 12 of KRAS in frozen tumors were determined, as previously described. ). This could be attributable to radiation effects because the recurrent tumor and normal mucosa samples were taken from the previously radiated field. Interestingly, after AMG-479 treatment, the expression signature reverted to the pattern observed in the pre-cetuximab-treated tumor which was sensitive to cetuximab.
The differentially expressed genes were further interrogated using IPA. The statistically significant networks of genes were those involved in DNA replication, recombination and repair, cell cycle, cellular assembly and organization, cell signaling, and immune response. One of the AMG-479-modulated genes with statistical significance was DHFR ( Figure  3B ) which was downregulated by AMG-479. DHFR is the binding target of MTX and its active metabolite, which results in S-phase cell cycle inhibition. 2 Eight additional genes in the folate biosynthesis pathway were not significantly altered by AMG-479. Decrease in the protein level of DHFR after AMG-479 treatment was confirmed by Western blot (Figure 2) . The tumor was negative for human papillomavirus infection or mutations in EGFR tyrosine kinase (TK) domain or KRAS. Additionally, this tumor was 1 of the tumors analyzed for EGFR gene copy number by fluorescent in situ hybridization in our previous study, and shown to have normal EGFR gene copy number. 3 
DISCUSSION
Recently, the dearth of therapeutic options for HNSCC has motivated the search for molecularly targeted therapies. One of the most common approaches has been inhibition of receptor tyrosine kinases (RTK) using either small molecules that bind to the TK domain of the receptors, or antibodies against epitopes located at the extracellular domains or against their ligands. Although recent therapeutic successes of small molecule RTK inhibitors have been linked to oncogenic dependency, usually caused by mutations in the functional TK domains, 4,5 the mechanism(s) of response to RTK inhibition by antibody-based targeted agents such as cetuximab, bevacizumab, or trastuzumab is less clear. The mechanism of action could be a direct inhibition of signal transduction through the inhibited receptors, but indirect mechanisms such as antibody-dependent cell-mediated cytotoxicity may play a role. 6 The most studied molecular target in HNSCC has been EGFR due to frequent overexpression in tumors compared to normal mucosal epithelia. 7 There is also increasing evidence for IGF-1R as a potential molecular target in HNSCC. 8 The IGF-1R is highly expressed in HNSCC compared to normal mucosal epithelia, and IGF-1 stimulates S-phase transition in a phosphoinositide-3-kinase/AKT and mitogen-activated protein kinase-dependent manner in HNSCC cell lines. 8, 9 The findings in our patient were consistent with the current data indicating that AMG-479 downregulates IGF-1R and AKT. 10 However, the tumor rapidly grew in the setting of effective target inhibition. It is unclear which signaling pathway is the dominant compensatory pathway for IGF-1R. When AMG-479-modulated genes were interrogated by IPA, multiple networks were identified suggesting the interconnected nature of the signaling pathways that are affected by inhibition of a single receptor. For example, the EGFR pathway may be involved considering the expression signature reverted to the pattern in the pre-cetuximab treated tumor after AMG-479. Although AKT activation through IGF-1R is independent of EGFR, activation of mitogen-activated protein kinase is thought to be mediated through crosstalk between EGFR and IGF-1R in oral carcinoma cells, probably through IGF-1 stimulation of matrix metalloproteinases (MMPs), release of EGFR ligands, and subsequent activation of EGFR. 11, 12 In addition, EGFR and IGF-1R are known to heterodimerize upon receptor activation, and a combination of EGFR and IGF-1R inhibitors is more effective in reducing cell proliferation and migration compared to each inhibitor alone. 8 The clinical observation that the patient regained cetuximab sensitivity upon rechallenge after having progressive disease suggests that AMG-479 may modulate cetuximab sensitivity.
The dramatic response to MTX with an unusual degree of sensitivity has not been reported using MTX as the fifth-line treatment in a recurrent/metastatic setting. Possible explanations for this response are: (1) an MTX-specific response due to downregulation of DHFR after AMG-479, (2) cell cycle-specific effect due to increased proliferation as a compensatory response to IGF-1R inhibition, or (3) decreased AKT signaling by AMG-479 and subsequently increased proapoptotic response to a cytotoxic agent. One may speculate that the response was MTX-specific due to downregulation of DHFR, because increased expression or activating mutations in DHFR have been associated with MTX resistance. 13 There is also evidence that a targeted agent such as gefitinib can affect the response to other cell cyclespecific cytotoxic agents such as paclitaxel. Solit et al 14 reported that continuous inhibition of EGFR antagonized the effects of paclitaxel, a mitosis-specific cytotoxic agent, by causing cell cycle arrest.
In the development of novel targeted therapeutics, the antitumor effects of specific antibodies as a monotherapy in the treatment of solid tumors have been disappointing with minimal response rates. 15, 16 However, the therapeutic strategy to combine antibodybased agents with existing chemotherapies has been extremely successful in breast cancer, non-small cell lung cancer, colon cancer, and HNSCC. 15, [17] [18] [19] This report supports the rationale for combination therapies using antibody-based targeted agents as chemosensitizers for conventional cytotoxic agents. In contrast to the general perception of targeted agents being less toxic than cytotoxic agents, our findings suggest that the use of a targeted agent alone may even be harmful by activating compensatory pathways. This brings into question the validity of limiting the evaluation of targeted agents based on response rates in monotherapy phase II trials. This case report suggests that the clinical development of IGF-1R inhibitors in combination with cetuximab or MTX warrants further investigation in refractory HNSCC.
